Download presentation
Presentation is loading. Please wait.
Published byMelvyn Hodges Modified over 5 years ago
1
Risk Factors for Developing Postthymectomy Myasthenia Gravis in Thymoma Patients
Yoshito Yamada, MD, PhD, Shigetoshi Yoshida, MD, PhD, Takekazu Iwata, MD, PhD, Hidemi Suzuki, MD, PhD, Tetsuzo Tagawa, MD, PhD, Teruaki Mizobuchi, MD, PhD, Naoki Kawaguchi, MD, PhD, Ichiro Yoshino, MD, PhD The Annals of Thoracic Surgery Volume 99, Issue 3, Pages (March 2015) DOI: /j.athoracsur Copyright © 2015 The Society of Thoracic Surgeons Terms and Conditions
2
Fig 1 Tree diagram of the thymoma patients in this study. The scheme shows patients categorized by preoperative (preop) and postoperative (postop) thymectomy myasthenia gravis (MG) and preoperative level of acetylcholine receptor antibody (AchR-Ab). (Minus symbol [−] = without MG; plus symbol [+] = with MG.) The Annals of Thoracic Surgery , DOI: ( /j.athoracsur ) Copyright © 2015 The Society of Thoracic Surgeons Terms and Conditions
3
Fig 2 Kaplan-Meier curves for freedom from myasthenia gravis (MG) generated using (A) preoperative acetylcholine receptor antibodies (AchR-Ab) test results (dotted line = AchR-Ab < 0.2; solid line = AchR-Ab ≥ 0.2); (B) World Health Organization (WHO) histologic classification of thymoma (dotted line = type A/AB; solid line = type B1–3); and (C) completeness of resection (dotted line = complete [R0]; solid line = incomplete [R1, 2]). These three variables showed significant differences in log rank tests. The Annals of Thoracic Surgery , DOI: ( /j.athoracsur ) Copyright © 2015 The Society of Thoracic Surgeons Terms and Conditions
4
Fig 3 Box plot showing that the acetylcholine receptor antibody (AchR-Ab) level at the onset of myasthenia gravis (MG) after thymectomy was significantly higher than the level before surgery (p = 0.036). Outliers are shown as asterisks. The Annals of Thoracic Surgery , DOI: ( /j.athoracsur ) Copyright © 2015 The Society of Thoracic Surgeons Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.